Rudolfs Cimdins Riga Biomaterials Innovation and Development Centre, Faculty of Materials Science and Applied Chemistry, Institute of General Chemical Engineering, Riga Technical University, Pulka 3, LV-1007 Riga, Latvia.
Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
Biomolecules. 2023 Mar 2;13(3):462. doi: 10.3390/biom13030462.
Even with decades of research studies behind octacalcium phosphate (OCP), determination of OCP phase formation has proved to be a cumbersome challenge. Even though obtaining a large quantity of OCP is important for potential clinical uses, it still remains a hindrance to obtain high yields of pure OCP. Taking that into consideration, the purpose of this study was to scale-up OCP synthesis for the first time and to use a multi-technique approach to follow the phase transformation pathway at multiple time points. In the present study, OCP has been synthesized from α-tricalcium phosphate (α-TCP), and subsequently scaled-up tenfold and hundredfold (100 mg → 10 g). The hydrolysis mechanism has been followed and described by using XRD and FTIR spectroscopy, as well as Raman and SEM. Gradual transformation into the OCP phase transpired through dicalcium phosphate dihydrate (brushite, DCPD, up to ~36%) as an intermediary phase. Furthermore, the obtained transitional phases and final OCP phases (across all scale-up levels) were tested with human bone marrow-derived mesenchymal stem cells (hBMSCs), in order to see how different phase mixtures affect the cell viability, and also to corroborate the safety of the scaled-up product. Twelve out of seventeen specimens showed satisfactory percentages of cell viability and confirmed the prospective use of scaled-up OCP in further in vitro studies. The present study, therefore, provides the first scale-up process of OCP synthesis, an in depth understanding of the formation pathway, and investigation of the parameters able to contribute in the OCP phase formation.
尽管已经有几十年的研究基础,但八钙磷酸盐(OCP)的相形成仍被证明是一个繁琐的挑战。尽管获得大量的 OCP 对于潜在的临床应用很重要,但它仍然是获得高纯度 OCP 的产量的障碍。考虑到这一点,本研究的目的是首次扩大 OCP 的合成规模,并采用多种技术手段在多个时间点跟踪相转变途径。在本研究中,OCP 是由α-磷酸三钙(α-TCP)合成的,随后将其放大十倍和一百倍(100mg→10g)。使用 XRD 和 FTIR 光谱、拉曼和 SEM 跟踪和描述了水解机制。通过二水合磷酸氢钙(DCPD,直至约 36%)作为中间相,逐渐转化为 OCP 相。此外,对获得的过渡相和最终的 OCP 相(在所有放大水平上)进行了人骨髓间充质干细胞(hBMSCs)的测试,以观察不同的相混合物如何影响细胞活力,并证实放大产物的安全性。十七个标本中有十二个显示出满意的细胞活力百分比,证实了放大 OCP 在进一步的体外研究中的应用前景。因此,本研究提供了 OCP 合成的首次放大过程、对形成途径的深入理解以及对能够促进 OCP 相形成的参数的研究。